MIM
PCVX icon

MetLife Investment Management’s Vaxcyte PCVX Stock Holding History

MetLife Investment Management’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.45M Buy
76,628
+8,774
+13% +$477K 0.02% 713
2026
Q1 		$3.94M Buy
67,854
+4,047
+6% +$220K 0.02% 734
2025
Q4 		$2.94M Sell
63,807
-2,759
-4% -$123K 0.01% 874
2025
Q3 		$2.4M Sell
66,566
-8,401
-11% -$278K 0.01% 1002
2025
Q2 		$2.44M Buy
74,967
+2,779
+4% +$91.1K 0.01% 908
2025
Q1 		$2.73M Sell
72,188
-2,315
-3% -$185K 0.01% 898
2024
Q4 		$6.1M Buy
74,503
+6,670
+10% +$662K 0.03% 452
2024
Q3 		$7.75M Buy
67,833
+4,866
+8% +$439K 0.04% 330
2024
Q2 		$4.75M Buy
62,967
+8,970
+17% +$611K 0.03% 511
2024
Q1 		$3.69M Buy
53,997
+4,726
+10% +$327K 0.02% 660
2023
Q4 		$3.09M Hold
49,271
– – 0.02% 751
2023
Q3 		$2.51M Buy
49,271
+826
+2% +$40.8K 0.02% 797
2023
Q2 		$2.42M Buy
48,445
+10,869
+29% +$515K 0.02% 856
2023
Q1 		$1.41M Hold
37,576
– – 0.01% 1054
2022
Q4 		$1.8M Buy
37,576
+10,053
+37% +$395K 0.01% 943
2022
Q3 		$661K Hold
27,523
– – 0.01% 1436
2022
Q2 		$599K Buy
27,523
+3,834
+16% +$88.7K ﹤0.01% 1537
2022
Q1 		$572K Buy
23,689
+8,743
+58% +$191K ﹤0.01% 1688
2021
Q4 		$356K Hold
14,946
– – ﹤0.01% 1697
2021
Q3 		$379K Hold
14,946
– – ﹤0.01% 1695
2021
Q2 		$336K Buy
14,946
+3,238
+28% +$66.3K ﹤0.01% 1812
2021
Q1 		$231K Buy
11,708
+3,846
+49% +$96.8K ﹤0.01% 1977
2020
Q4 		$209K Hold
7,862
– – ﹤0.01% 1961
2020
Q3 		$388K Buy
+7,862
New +$313K ﹤0.01% 1503

Other funds holding PCVX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

MetLife Investment Management's PCVX Position: Q2 2026 in Review

MetLife Investment Management increased its Vaxcyte (PCVX) stake by 13% in Q2 2026, buying an estimated $477K and bringing the position to 76,628 shares worth $4.45M. The position accounts for 0.02% of the portfolio, ranked #713.

MetLife Investment Management first reported a position in PCVX in Q3 2020 and has held it in 24 quarters since. The position peaked at $7.75M in Q3 2024. 331 funds tracked by Wall St. Rank hold PCVX as of Q2 2026.

  • MetLife Investment Management held 76,628 shares of Vaxcyte worth $4.45M as of Q2 2026.
  • MetLife Investment Management bought 8,774 Vaxcyte shares in Q2 2026, an estimated $477K.
  • Vaxcyte made up 0.02% of MetLife Investment Management's portfolio in Q2 2026, its #713 holding.
  • MetLife Investment Management first reported a position in Vaxcyte in Q3 2020 and has held it in 24 quarters since.
  • MetLife Investment Management's Vaxcyte position peaked at $7.75M in Q3 2024.
  • 331 funds tracked by Wall St. Rank held Vaxcyte as of Q2 2026.

Based on MetLife Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.